Have you or a loved one been diagnosed with HER2+ Metastatic Colorectal Cancer?

If so, learn more about MOUNTAINEER, a study testing the effects of an investigational medicine combination in participants with HER2+ metastatic or unresectable colorectal cancer.

Have you or a loved one been diagnosed with HER2+ Metastatic Colorectal Cancer?

If so, learn more about MOUNTAINEER, a study testing the effects of an investigational medicine combination in participants with HER2+ metastatic or unresectable colorectal cancer.

Have you or a loved one been diagnosed with HER2+ Metastatic Colorectal Cancer?

If so, learn more about MOUNTAINEER, a study testing the effects of an investigational medicine combination in participants with HER2+ metastatic or unresectable colorectal cancer.

Have you or a loved one been diagnosed with HER2+ Metastatic Colorectal Cancer?

If so, learn more about MOUNTAINEER, a study testing the effects of an investigational medicine combination in participants with HER2+ metastatic or unresectable colorectal cancer.

Have you or a loved one been diagnosed with HER2+ Metastatic Colorectal Cancer?

If so, learn more about MOUNTAINEER, a study testing the effects of an investigational medicine combination in participants with HER2+ metastatic or unresectable colorectal cancer.

Slider
Seagen MOUNTAINEER HER2+ Metastatic Colorectal Cancer Study

MOUNTAINEER is a Phase 2 study of tucatinib plus trastuzumab in people with HER2-positive (HER2+) colorectal cancer. This trial studies how the drug tucatinib works and how safe it is when given with trastuzumab and when given by itself. The participants in this trial have HER2+ metastatic or unresectable colorectal cancer. Metastatic means that the cancer has spread to other parts of the body. Unresectable means cancer that cannot be completely removed with surgery.

The use of tucatinib described here is experimental. Because of that, not all risks are known before starting a clinical trial.

Facts About the MOUNTAINEER Study

HER2+ Colorectal Cancer Study
HER2+ Colorectal Cancer Study

Why is this study being done?

Some people with metastatic colorectal cancer may have a protein on their tumor called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth and spread of cancer cells. This study uses experimental treatments that target HER2 proteins to kill the cancer cells.

 

More about the study

Participants in this study will be randomly assigned to get either tucatinib alone or tucatinib with trastuzumab. This is an open-label study, which means both the researcher and the participant will know the treatment they are receiving.

  • Participants who take part in the study will take tucatinib twice a day by mouth
  • Participants who take part in the study who also get trastuzumab will get it as an infusion into a vein (also called “IV”) once every 3 weeks
  • If their cancer is not getting better, participants who get tucatinib alone may be able to start taking tucatinib and trastuzumab
HER2+ Colorectal Cancer Study

What is this study looking for?

The purpose of this study is to find out if tucatinib and trastuzumab work for colorectal cancer. To do that, this study will look at:

  • The number of participants whose cancer looks like it gets better on scans
  • How long it takes for cancer to spread or get worse after starting treatment with tucatinib and trastuzumab
  • How long participants live after treatment

This is not a complete list of outcomes that will be observed in this clinical study

 

What can you expect from being in this study?

If you enroll in the MOUNTAINEER study, you may:

  • need to travel to the clinical trial site location
  • be in the study for several years
  • need blood tests taken or other tests such as heart monitoring — this helps researchers learn how the drug is working

You may be eligible for travel reimbursement:
If you enroll in this study, you may receive reimbursement (up to $500 per study visit) for approved travel expenses associated with participating in the study. Research costs related to your participation in the study, such as study drug, extra doctor visits and lab and imaging tests performed, will be covered. You may be responsible for routine medical costs; study team staff will discuss these with you. Your cancer prognosis may or may not improve by taking part in the MOUNTAINEER study. People who are in the study may stop at any time.

For more information on the MOUNTAINEER study, please contact the Seagen Trial Information Support at 866-333-7436 or clinicaltrials@seagen.com. You can also visit https://clinicaltrials.gov/ct2/show/NCT03043313.